News | January 01, 2026
Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
Once finalized, cough syrups will no longer be available for over-the-counter sale
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Subscribe To Our Newsletter & Stay Updated
